Deals

Astellas Inks Exclusive Option and License Deal for Audax's DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy
Astellas PharmaAudax Biosciences

Astellas Inks Exclusive Option and License Deal for Audax’s DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Astellas Pharma Inc. (TYO: 4503) and Audax Biosciences Pty Ltd jointly announced that the two parties have entered into an exclusive option and license agreement for DAX-044, Audax's lead oncology…

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
MGI TechSequanta Technologies

MGI Tech and Sequanta Technologies Launch Advanced DCS Lab to Accelerate Omics Research

AIBioGeometry

Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery

AlibabaAlibaba Health

Alibaba Health Forges Strategic Partnerships with Viatris and Chinese Pharma Companies for Digital Health Expansion

Bao PharmaceuticalsCentergene Pharmaceuticals

Shanghai Bao Pharmaceutical and Subsidiary Secure Commercialization Rights Deal for SJ02 with Organon China

Show More